Literature DB >> 19200171

Health care services utilization stratified by virological and immunological markers of HIV: evidence from a universal health care setting.

E F Druyts1, B Yip, V D Lima, T A Burke, D Lesovski, K A Fernandes, C W McInnes, C A Rustad, J S G Montaner, R S Hogg.   

Abstract

OBJECTIVE: The aim of the study was to determine rates of utilization of in-patient, out-patient and laboratory services stratified by virological and immunological markers of HIV disease among patients on antiretroviral treatment in British Columbia, Canada.
METHODS: We estimated resource utilization for in-patient visits, out-patient visits, and laboratory tests among patients initiating antiretroviral treatment between 1 April 1994 and 31 December 2000, with follow-up to 31 March 2001. Resource use was stratified by CD4 cell count and plasma HIV viral load (pVL) at the time of utilization and rates per 100 patient-years were calculated for each health care resource.
RESULTS: A total of 2718 patients were included in our analyses. The overall rates of in-patient visits, out-patient visits, and laboratory tests were 902, 3001 and 840 per 100 patient-years, respectively. Utilization was higher for patients with low CD4 cell counts and high pVLs when compared with patients with high CD4 cell counts and low pVLs.
CONCLUSIONS: Patients with low CD4 cell counts and high pVLs had the highest use of health care services. Regular follow-up with health care providers in an out-patient setting, allowing for proper monitoring and maintenance of HIV care, is important in minimizing unnecessary and potentially costly in-patient care.

Entities:  

Mesh:

Year:  2009        PMID: 19200171     DOI: 10.1111/j.1468-1293.2008.00656.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  6 in total

1.  Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.

Authors:  Ola Ghatnekar; Catharina Hjortsberg; Magnus Gisslén; Stefan Lindbäck; Mickael Löthgren
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.

Authors:  Anita J Brogan; Erik Smets; Josephine A Mauskopf; Sarah A L Manuel; Ines Adriaenssen
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

3.  Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries.

Authors:  Janet M Raboud; Mona R Loutfy; DeSheng Su; Ahmed M Bayoumi; Marina B Klein; Curtis Cooper; Nima Machouf; Sean Rourke; Sharon Walmsley; Anita Rachlis; P Richard Harrigan; Marek Smieja; Christos Tsoukas; Julio S G Montaner; Robert S Hogg
Journal:  BMC Infect Dis       Date:  2010-02-25       Impact factor: 3.090

4.  Which health care facilities do adult Malawian antiretroviral therapy patients utilize during intercurrent illness?A cross sectional study.

Authors:  Caroline Masangalawe; Akuzike Kandulu; Joep J van Oosterhout
Journal:  BMC Health Serv Res       Date:  2011-12-21       Impact factor: 2.655

5.  Optimizing an HIV testing program using a system dynamics model of the continuum of care.

Authors:  Sarah Kok; Alexander R Rutherford; Reka Gustafson; Rolando Barrios; Julio S G Montaner; Krisztina Vasarhelyi
Journal:  Health Care Manag Sci       Date:  2015-01-17

6.  Hospitalization of HIV positive patients in a referral tertiary care hospital in Antananarivo Madagascar, 2010-2016: Trends, causes and outcome.

Authors:  Mihaja Raberahona; Tiana Razafinambinintsoa; Volatiana Andriananja; Njaratiana Ravololomanana; Juliana Tongavelona; Rado Rakotomalala; Johary Andriamamonjisoa; Radonirina Lazasoa Andrianasolo; Rivonirina Andry Rakotoarivelo; Mamy Jean de Dieu Randria
Journal:  PLoS One       Date:  2018-08-30       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.